BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

In a study involving patients with severe hemophilia A, an injection of the novel fusion protein BIVV001 resulted in a duration of factor VIII activity that was up to four times as long as that for recombinant factor VIII, an increase that may signal the possibility of weekly therapy.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 383; no. 11; pp. 1018 - 1027
Main Authors Konkle, Barbara A, Shapiro, Amy D, Quon, Doris V, Staber, Janice M, Kulkarni, Roshni, Ragni, Margaret V, Chhabra, Ekta S, Poloskey, Stacey, Rice, Kara, Katragadda, Suresh, Fruebis, Joachim, Benson, Craig C
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 10.09.2020
Subjects
Anaphylaxis
Body weight
Coagulation factors
Drug dosages
Factor VIII deficiency
Fusion protein
Hemophilia
Hypersensitivity
Hypothesis testing
Injection
Intravenous administration
Patients
Pharmacokinetics
Plasma
Polypeptides
Proteins
Quality of life
Von Willebrand factor
Online AccessGet full text

Cover

More Information
Summary:In a study involving patients with severe hemophilia A, an injection of the novel fusion protein BIVV001 resulted in a duration of factor VIII activity that was up to four times as long as that for recombinant factor VIII, an increase that may signal the possibility of weekly therapy.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2002699